XYP-001

XYP-001 is an inhaled formulation of the anti-fibrotic agent pirfenidone, developed by Joincare Pharmaceutical Group for the treatment of idiopathic pulmonary fibrosis (IPF). While oral pirfenidone is a standard-of-care treatment for IPF, its use is often limited by systemic side effects such as gastrointestinal toxicity and photosensitivity. XYP-001 is designed to be delivered directly to the lungs via a nebulizer, potentially allowing for higher therapeutic concentrations at the site of disease while minimizing systemic drug levels and associated adverse events. The drug functions by inhibiting the production of pro-fibrotic and pro-inflammatory cytokines, including transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha). It is currently undergoing clinical evaluation in Phase 2 trials to assess its safety and efficacy in patients with IPF.

Other names

Pirfenidone for inhalationInhaled pirfenidonePirfenidone solution for inhalation